Teva Clinical Trials: 603 Led Studies

Archive historyOct 2022 to Jun 2026

131 recorded changes across Teva trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 25 of these trials. One is shown below.

Status changeStatus moved to active not recruiting from recruitingNCT06052267 · recorded 1 Jun 2026

Track to read them

+127 more recorded changes · Track a drug to see every change the night it lands

Track pembrolizumab

Most active programmes

The drugs appearing most often across Teva's recently active trials. Comparator arms are excluded.

Fremanezumab5 trials
Alprazolam Extended-Release 3 mg Tablets4 trials
TEV-562863 trials
TEV-562482 trials
TEV-534082 trials
Pembrolizumab2 trials

Upcoming readouts

Next primary completion dates among Teva's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Sept 2026A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propi…Phase 3
Sept 2027TOPAS-MSA: A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atr…Phase 2
May 2029An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyPhase 2

Top therapeutic areas

Conditions studied most often across Teva's recently active trials.

Migraine5 trials
Asthma4 trials
Schizophrenia3 trials
Multiple Myeloma3 trials
Multiple System Atrophy2 trials
Crohn Disease2 trials

Teva trials

The 50 most significant of Teva's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseNCT06807463TEV-53408	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	50 est.	15 Sept 2026
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating VitiligoNCT06625177TEV-53408	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	38 est.	18 Sept 2026
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaNCT06664619Fp/ABS	Phase 3	Locked · track to reveal	OngoingRecruiting	724 est.	19 Sept 2026
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsNCT06052267TEV-56248	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	2,772 est.	31 Oct 2026
A Trial to Assess TEV-56286 at Different Doses in Healthy ParticipantsNCT07674940TEV-56286 Dose A	Phase 1	Not yet scored	OngoingRecruiting	60 est.	15 Jan 2027
TOPAS-MSAA Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System AtrophyNCT06568237TEV-56286	Phase 2	Locked · track to reveal	OngoingRecruiting	350 est.	15 Sept 2027
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyNCT07197866TEV-56286	Phase 2	Locked · track to reveal	OngoingRecruiting	200 est.	3 May 2029
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsNCT06480552TEV-56278	Phase 1	Locked · track to reveal	OngoingRecruiting	240 est.	26 May 2029
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseNCT05668013TEV-48574 Dose Regimen A	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	247 est.	5 Jan 2026
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in ChinaNCT07601516Deutetrabenazine	Phase 4	Locked · track to reveal	Completed	50 est.	24 Oct 2025
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisNCT06742957Tapinarof Cream 1%	Phase 3	Locked · track to reveal	Completed	560 est.	7 Oct 2025
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsNCT04530110Fremanezumab	Phase 3	Locked · track to reveal	Completed	506 est.	15 Aug 2025
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With SchizophreniaNCT06315283TV-44749	Phase 1	Locked · track to reveal	Completed	153 est.	14 Aug 2025
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With SchizophreniaNCT06253546TV-44749 318mg	Phase 1	Locked · track to reveal	Completed	24 est.	12 Jun 2025
A Study to Assess New Formulations of TEV-56286NCT06911567TEV-56286 Test	Phase 1	Locked · track to reveal	Completed	47 est.	22 May 2025
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective DisorderNCT06319170Olanzapine Extended Release	Phase 1	Locked · track to reveal	Completed	106 est.	15 Jan 2025
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeNCT04464707Fremanezumab	Phase 3	Locked · track to reveal	Completed	292 est.	29 Nov 2024
Mass Balance Clinical Trial With TEV-56286NCT06627231TEV-56286	Phase 1	Locked · track to reveal	Completed	8 est.	29 Nov 2024
RELIEVE UCCDA Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseNCT05499130TEV-48574	Phase 2	Locked · track to reveal	Completed	290 est.	12 Nov 2024
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years OldNCT06290102TEV-56248	Phase 1	Locked · track to reveal	Completed	30 est.	1 Oct 2024
iinnovate-1A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaNCT03215030Modakafusp alfa	Phase 1	Locked · track to reveal	StoppedTerminated	272 est.	1 Jul 2024
iinnovate-2A Study of Modakafusp Alfa in Adult Participants With Multiple MyelomaNCT05556616Modakafusp alfa	Phase 1	Locked · track to reveal	StoppedTerminated	15 est.	4 Jun 2024
iinnovate-3A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaNCT05590377Modakafusp Alfa	Phase 1	Locked · track to reveal	StoppedTerminated	15 est.	22 May 2024
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaNCT04976192TEV-45779	Phase 3	Locked · track to reveal	Completed	608 est.	5 Apr 2024
SOLARISA Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaNCT05693935TV-44749	Phase 3	Locked · track to reveal	Completed	675 est.	19 Mar 2024
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeNCT04458857Fremanezumab	Phase 3	Locked · track to reveal	Completed	235 est.	13 Mar 2024
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineNCT05458011Fremanezumab	Phase 3	Locked · track to reveal	Completed	365 est.	31 Jan 2024
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsNCT04157517Modakafusp Alfa	Phase 1	Locked · track to reveal	StoppedTerminated	45 est.	20 Dec 2023
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT04392648TAK-573	Phase 1	Locked · track to reveal	StoppedWithdrawn	0 est.	10 Nov 2023
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne VulgarisNCT05550337Trifarotene 0.005 % Topical Cream	Phase 3	Locked · track to reveal	Completed	807 est.	9 May 2023
CONNECT1A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With AsthmaNCT03890666Albuterol eMDPI DS	Phase 4	Locked · track to reveal	Completed	333 est.	4 Oct 2021
AIM-TDAddressing Involuntary Movements in Tardive DyskinesiaNCT02291861SD-809	Phase 3	Locked · track to reveal	Completed	298 est.	19 Aug 2016
Levetiracetam 1000 mg Under Fasting ConditionsNCT00859521Levetiracetam	Phase 1	Locked · track to reveal	Completed	30 est.	Jan 2007
Levetiracetam 1000 mg Under Non-Fasting ConditionsNCT00859430Levetiracetam	Phase 1	Locked · track to reveal	Completed	22 est.	Jan 2007
Mycophenolate Mofetil 250 mg Capsules Under Fed ConditionsNCT00910663Mycophenolate Mofetil	Phase 1	Locked · track to reveal	Completed	60 est.	Nov 2006
A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting ConditionsNCT00830206Azithromycin	Phase 1	Locked · track to reveal	Completed	80 est.	Jan 2006
A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting ConditionsNCT00830336Azithromycin	Phase 1	Locked · track to reveal	Completed	80 est.	Nov 2005
Cefdinir Capsules 300 mg, Non-fastingNCT00834535Cefdinir Capsules 300 mg	Phase 1	Locked · track to reveal	Completed	32 est.	Aug 2005
Cefdinir Capsules 300 mg, FastingNCT00835484Cefdinir Capsules 300 mg	Phase 1	Locked · track to reveal	Completed	32 est.	Jul 2005
Granisetron 1 mg Tablets, Non-fastingNCT00834522Granisetron hydrochloride 1 mg tablets	Phase 1	Locked · track to reveal	Completed	80 est.	Jul 2005
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting ConditionsNCT00829426Alprazolam Extended-Release 3 mg Tablets	Phase 1	Locked · track to reveal	Completed	32 est.	Jun 2005
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting ConditionsNCT00830024Alprazolam Extended-Release 3 mg Tablets	Phase 1	Locked · track to reveal	Completed	36 est.	Jun 2005
Cefdinir for Oral Suspension 250 mg/5mL, FastingNCT00834574Cefdinir for oral suspension 250 mg/5mL	Phase 1	Locked · track to reveal	Completed	32 est.	Mar 2005
Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting ConditionsNCT00829309Pravastatin	Phase 1	Locked · track to reveal	Completed	16 est.	Mar 2005
Cefdinir for Oral Suspension 250 mg/5mL, Non-fastingNCT00835549Cefdinir for oral suspension 250 mg/5mL	Phase 1	Locked · track to reveal	Completed	32 est.	Mar 2005
Trandolapril 4 mg Tablet Under Non-Fasting ConditionsNCT00840073Trandolapril 4 mg Tablets	Phase 1	Locked · track to reveal	Completed	50 est.	Nov 2004
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed ConditionsNCT01149733Tamsulosin	Phase 1	Locked · track to reveal	Completed	32 est.	Nov 2004
Trandolapril 4 mg Tablet Under Fasting ConditionsNCT00840632Trandolapril 4 mg Tablets	Phase 1	Locked · track to reveal	Completed	40 est.	Nov 2004
Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.NCT00835081Cefadroxil 500 mg Capsules	Phase 1	Locked · track to reveal	Completed	26 est.	Oct 2004
Cefadroxil 500 mg Capsules Under Fasting ConditionsNCT00834275Cefadroxil 500 mg Capsules	Phase 1	Locked · track to reveal	Completed	26 est.	Oct 2004

View all trials603

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Phase 2Active, not recruitingNCT06807463 ↗

Primary completion: Sept 2026; estimated
Enrollment: 50; estimated
Start: Mar 2025; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Celiac Disease

Interventions

TEV-53408
Placebo

Brief summary

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Enrollment change · 2

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Phase 1Active, not recruitingNCT06625177 ↗

Primary completion: Sept 2026; estimated
Enrollment: 38; estimated
Start: Nov 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Vitiligo

Interventions

TEV-53408

Brief summary

The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Mar 2026

Enrollment change · 3

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Phase 3RecruitingNCT06664619 ↗

Primary completion: Sept 2026; estimated
Enrollment: 724; estimated
Start: Dec 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Asthma

Interventions

Fp/ABS
FP
ABS
Placebo

Brief summary

The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Phase 3Active, not recruitingNCT06052267 ↗

Primary completion: Oct 2026; estimated
Enrollment: 2,772; estimated
Start: Aug 2023; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Asthma

Interventions

TEV-56248
Albuterol sulfate

Brief summary

The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jun 2026

Status change · 3

Enrollment change · 2

Completion date move · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

TOPAS-MSA: A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Phase 2RecruitingNCT06568237 ↗

Primary completion: Sept 2027; estimated
Enrollment: 350; estimated
Start: Oct 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple System Atrophy

Interventions

TEV-56286
Placebo

Brief summary

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Completion date move · 1

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Phase 2RecruitingNCT07197866 ↗

Primary completion: May 2029; estimated
Enrollment: 200; estimated
Start: Sept 2025; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple System Atrophy

Interventions

TEV-56286

Brief summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1RecruitingNCT06480552 ↗

Primary completion: May 2029; estimated
Enrollment: 240; estimated
Start: Jul 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Advanced Solid Tumors

Interventions

TEV-56278
Pembrolizumab

Brief summary

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2024

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Phase 2Active, not recruitingNCT05668013 ↗

Primary completion: Jan 2026; actual
Enrollment: 247; estimated
Start: Jan 2023; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Crohn Disease
Colitis, Ulcerative

Interventions

TEV-48574 Dose Regimen A
TEV-48574 Dose Regiment B

Brief summary

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: * evaluate the efficacy of 2 different…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Mar 2026

Completion date move · 4

Enrollment change · 2

Status change · 2

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Phase 3CompletedNCT04530110 ↗

Primary completion: Aug 2025; actual
Enrollment: 506; estimated
Start: Sept 2020; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Migraine

Interventions

Fremanezumab

Brief summary

The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous…

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 Feb 2026

Status change · 5

Completion date move · 4

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Phase 1CompletedNCT06315283 ↗

Primary completion: Aug 2025; actual
Enrollment: 153; estimated
Start: Mar 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Schizophrenia

Interventions

TV-44749
Oral olanzapine

Brief summary

The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Oct 2025

Status change · 3

Completion date move · 3

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Phase 1CompletedNCT06253546 ↗

Primary completion: Jun 2025; actual
Enrollment: 24; estimated
Start: Mar 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Schizophrenia

Interventions

TV-44749 318mg
Oral Olanzapine 10mg/day
TV-44749 425mg
Oral Olanzapine 15mg/day
TV-44749 531mg
Oral Olanzapine 20mg/day

Brief summary

Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: * To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. * To evaluate the pharmacokinetics of oral…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2025

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Assess New Formulations of TEV-56286

Phase 1CompletedNCT06911567 ↗

Primary completion: May 2025; actual
Enrollment: 47; estimated
Start: Mar 2025; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Healthy Participants

Interventions

TEV-56286 Test
TEV-56286 Reference

Brief summary

The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Aug 2025

Completion date move · 1

Status change · 1

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Phase 1CompletedNCT06319170 ↗

Primary completion: Jan 2025; actual
Enrollment: 106; estimated
Start: Mar 2024; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Schizophrenia, Schizoaffective Disorder

Interventions

Olanzapine Extended Release
Olanzapine Immediate Release

Brief summary

The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine. Another secondary objective is to characterize the pharmacokinetics of ZYPREXA. The planned duration of the…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Feb 2026

Status change · 3

Enrollment change · 2

Completion date move · 2

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

Phase 3CompletedNCT04464707 ↗

Primary completion: Nov 2024; actual
Enrollment: 292; estimated
Start: Sept 2020; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Migraine

Interventions

Fremanezumab
Placebo

Brief summary

The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Jan 2025

Completion date move · 5

Enrollment change · 2

Status change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

RELIEVE UCCD: A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Phase 2CompletedNCT05499130 ↗

Primary completion: Nov 2024; actual
Enrollment: 290; estimated
Start: Sept 2022; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Crohn Disease
Colitis, Ulcerative

Interventions

TEV-48574
Placebo

Brief summary

The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: * To evaluate the efficacy of 2…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jan 2025

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Phase 1CompletedNCT06290102 ↗

Primary completion: Oct 2024; actual
Enrollment: 30; estimated
Start: May 2024; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Asthma

Interventions

TEV-56248
Fp MDPI

Brief summary

The primary objectives of this study are: * To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma * To…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2025

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

iinnovate-1: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1TerminatedNCT03215030 ↗

Primary completion: Jul 2024; actual
Enrollment: 272; estimated
Start: Oct 2017; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple Myeloma

Interventions

Modakafusp alfa
Dexamethasone

Brief summary

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Nov 2025

Status change · 3

Completion date move · 3

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

iinnovate-2: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Phase 1TerminatedNCT05556616 ↗

Primary completion: Jun 2024; actual
Enrollment: 15; estimated
Start: Jan 2023; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple Myeloma

Interventions

Modakafusp alfa
Lenalidomide
Bortezomib
Carfilzomib
Daratumumab
Pomalidomide

Brief summary

The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Sept 2025

Status change · 4

Completion date move · 2

Enrollment change · 2

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

iinnovate-3: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Phase 1TerminatedNCT05590377 ↗

Primary completion: May 2024; actual
Enrollment: 15; estimated
Start: Jan 2023; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple Myeloma

Interventions

Modakafusp Alfa
Daratumumab

Brief summary

The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Sept 2025

Status change · 3

Completion date move · 1

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Phase 3CompletedNCT04976192 ↗

Primary completion: Apr 2024; actual
Enrollment: 608; estimated
Start: Aug 2021; Teva Pharmaceuticals USA

Conditions

Chronic Urticaria

Interventions

TEV-45779
XOLAIR® Injection

Brief summary

The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2024

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

SOLARIS: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

Phase 3CompletedNCT05693935 ↗

Primary completion: Mar 2024; actual
Enrollment: 675; estimated
Start: Jan 2023; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Schizophrenia

Interventions

TV-44749
Placebo

Brief summary

The primary objective of this study is to evaluate the efficacy of TV-44749 in adult participants with schizophrenia. A key secondary objective is to further evaluate the efficacy of TV-44749 based on additional parameters in adult participants with schizophrenia. A secondary objective is to evaluate the safety and…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2025

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Phase 3CompletedNCT04458857 ↗

Primary completion: Mar 2024; actual
Enrollment: 235; estimated
Start: Jul 2020; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Migraine

Interventions

Fremanezumab
Placebo

Brief summary

The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jul 2024

Status change · 2

Completion date move · 2

Enrollment change · 2

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Phase 3CompletedNCT05458011 ↗

Primary completion: Jan 2024; actual
Enrollment: 365; estimated
Start: Sept 2022; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Migraine

Interventions

Fremanezumab
Placebo

Brief summary

Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Oct 2024

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1TerminatedNCT04157517 ↗

Primary completion: Dec 2023; actual
Enrollment: 45; estimated
Start: Dec 2019; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Neoplasms
Melanoma

Interventions

Modakafusp Alfa
Pembrolizumab

Brief summary

This study has 2 phases. The main aims of Phase 1b are: * to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors. * to learn how much modakafusp alfa adults can receive without getting any major side effects from it. The main aims of Phase 2 are: * to check for…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jan 2025

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Teva drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1WithdrawnNCT04392648 ↗

Primary completion: Nov 2023; estimated
Enrollment: 0; estimated
Start: Jun 2020; Teva Branded Pharmaceutical Products R&D LLC

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

TAK-573
Pomalidomide
Bortezomib
Cyclophosphamide
Dexamethasone

Brief summary

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

CONNECT1: A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

Phase 4CompletedNCT03890666 ↗

Primary completion: Oct 2021; actual
Enrollment: 333; estimated
Start: Oct 2020; Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Asthma

Interventions

Albuterol eMDPI DS
albuterol

Brief summary

This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health platform (DHP) (Cloud solution), and dashboard, to optimize outcomes in participants at least 13…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.